Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Hudson, Amanda L ^a,b   Weir, Chris ^a,b   Moon, Elizabeth ^a,b   Harvie, Rozelle ^a,b   Klebe, Sonja ^c   Clarke, Stephen J ^a,b   Pavlakis, Nick ^a,b   Howell, Viive M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKINE; GLUTATHIONE;

ANIMAL; BLOOD; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; IC50; IMMUNOLOGY; LYMPHOCYTE COUNT; MESOTHELIOMA; METABOLISM; MORTALITY; MULTIGENE FAMILY; PATHOLOGY; PHENOTYPE; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUTATHIONE; INHIBITORY CONCENTRATION 50; LYMPHOCYTE COUNT; MESOTHELIOMA; MULTIGENE FAMILY; PHENOTYPE; RATS;

EID: 84906499938     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06152     Document Type: Article

References (49)

1. WHO. Asbestos: elimination of asbestos-related diseases. Fact sheet No 343, July, 2010).
2. Sim, M. R. A worldwide ban on asbestos production and use: some recent progress, but more still to be done. Occup Environ Med 70, 1-2 (2013).
3. Olsen, N. J. et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 195, 271-274 (2011).
4. Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21, 2636-2644 (2003). (Pubitemid 46606305)
5. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. The Asbestos Diseases Research Institute Place published (2013).
6. Remon, J. et al.Malignant mesothelioma: New insights into a rare disease. Cancer Treat Rev (2012).
7. Zucali, P. A. et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37, 543-558 (2011).
8. Zauderer, M. G. & Krug, L. M. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 10, 42-47 (2012).
9. Yakisich, J. S. An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors. ISRN Pharmacol 2012, 513580 (2012).
10. Kamb, A.What's wrong with our cancer models? Nat Rev Drug Discov 4, 161-165 (2005). (Pubitemid 40277495)
11. Lowenstein, P. R. & Castro, M. G. Uncertainty in the translation of preclinical experiments to clinical trials. Why domost phase III clinical trials fail? Curr Gene Ther 9, 368-374 (2009).
12. Favoni, R. E., Daga, A.,Malatesta, P. & Florio, T. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br J Pharmacol 166, 532-553 (2012).
13. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat Rev Cancer 7, 645-658 (2007). (Pubitemid 47327410)
14. Abolhassani, M. et al. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice. Invest New Drugs (2011).
15. Craighead, J. E., Akley, N. J., Gould, L. B. & Libbus, B. L. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129, 448-462 (1987). (Pubitemid 18029988)
16. Shi, Y. et al. Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer 71, 370-371 (2011).
17. Kucharczuk, J. C. et al. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thorac Surg 60, 593-597; discussion 597-598 (1995).
18. Lardinois, D. et al. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg 131, 697-703 (2006).
19. Opitz, I. et al. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Eur J Cardiothorac Surg 31, 773-778 (2007).
20. Zhong, J., Lardinois, D., Szilard, J., Tamm, M. & Roth, M. Rat mesothelioma cell proliferation requires p38delta mitogen activated protein kinase and C/EBPalpha. Lung Cancer (2011).
21. Nutt, J. E. et al. The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 102, 553-560 (2010).
22. Kao, S. C. et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales dust diseases board. Clin Lung Cancer 14, 70-77 (2013).
23. Aronson, J. F. & Cristofalo, V. J. Culture of epithelial cells from the rat pleura. In Vitro 17, 61-70 (1981). (Pubitemid 12235632)
24. Bermudez, E., Libbus, B. &Mangum, J. B. Rat pleural mesothelial cells adapted to serum-free medium as a model for the study of growth factor effects. Cell Biol Toxicol 14, 243-251 (1998). (Pubitemid 28375845)
25. Swain, W. A., O'Byrne, K. J. & Faux, S. P. Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. Am J Physiol Lung Cell Mol Physiol 286, L859-865 (2004). (Pubitemid 38365073)
26. McDermott, M. et al. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front Oncol 4, 40 (2014).
27. Shukla, A. et al. Blocking of ERK1 and ERK2 sensitizes humanmesothelioma cells to doxorubicin. Mol Cancer 9, 314 (2010).
28. Goparaju, C.M. et al. Onconase mediated NFKbeta downregulation in malignant pleural mesothelioma. Oncogene 30, 2767-2777 (2011).
29. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J.& Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94, 703-708 (1994). (Pubitemid 24251002)
30. Davidson, J. D. et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64, 3761-3766 (2004). (Pubitemid 38697284)
31. Obata, T., Tanaka,M., Suzuki, Y.&Sasaki, T. The Role of Thymidylate Synthase in Pemetrexed-Resistant Malignant Pleural Mesothelioma Cells. Journal of Cancer Therapy 4, 1052-1059 (2013).
32. Kruh, G.D.&Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene 22, 7537-7552 (2003). (Pubitemid 37487175)
33. Kartalou, M. & Essigmann, J. M. Mechanisms of resistance to cisplatin. Mutat Res 478, 23-43 (2001). (Pubitemid 32530848)
34. Jean, D., Daubriac, J., Le Pimpec-Barthes, F., Galateau-Salle, F. & Jaurand, M. C. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 136, 277-293 (2012).
35. Iwanami, T. et al. Clinical significance of epithelial-mesenchymal transitionassociated markers in malignant pleural mesothelioma. Oncology 86, 109-116 (2014).
36. Soini, Y., Jarvinen, K., Kaarteenaho-Wiik, R. & Kinnula, V. The expression of Pglycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12, 1239-1245 (2001). (Pubitemid 32994751)
37. Shukla, S., Ohnuma, S. & Ambudkar, S. V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 12, 621-630 (2011).
38. Chirieac, L. R. et al. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am J Cancer Res 1, 14-24 (2011).
39. Yamaki, E. et al. Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype. Oncol Rep 29, 932-940 (2013).
40. Dallas, N. A. et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69, 1951-1957 (2009).
41. Guillot, F. et al. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine (2011).
42. Thomas-Schoemann, A. et al. Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer 129, 1511-1518 (2011).
43. Hodgkinson, V. C. et al. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? J Proteomics 75, 1276-1283 (2012).
44. Kitayama, J., Yasuda, K., Kawai, K., Sunami, E. & Nagawa, H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 11, 64 (2011).
45. Lissoni, P. et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 19, 135-140 (2004). (Pubitemid 39106939)
46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63 (1983). (Pubitemid 14203433)
47. Kao, S. C. et al. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology 43, 313-317 (2011).
48. Ordonez, N. G. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 38, 1-16 (2007). (Pubitemid 44880219)
49. Hu, Q. et al. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 90, 360-373 (2010).